Clinical Trial Detail

NCT ID NCT03322540
Title Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Incyte Corporation
Indications

non-small cell lung carcinoma

Therapies

Pembrolizumab

Epacadostat + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST